The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase II single arm, open label trial
{{output}}
We previously demonstrated that the anti-CD33 antibody drug conjugate, gemtuzumab ozogamicin (GO) binds CD33-expressing monocytic myeloid-derived suppressor cells (M-MDSCs), is internalised, and decreases their viability. Treatment of MDSCs with GO restores T-... ...
